Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release May 17 2024

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a press release regarding an exclusive licensing and supply agreement for Cabozantinib Tablets for the US market. The agreement involves MSN Laboratories manufacturing and supplying the generic version of CABOMETYX, while Zydus will handle marketing and distribution in the US. This partnership aims to enhance access to affordable medications for cancer patients. The total addressable market for Cabozantinib Tablets in the US is significant, highlighting the potential impact of this collaboration.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 17, 2024, titled "Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX��) for the US market".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases